East Bay’s Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease


It is the second deal within a year between the company, co-founded by Nobel laureate Jennifer Doudna, and Sanofi.

Previous FTC moves to block Iqvia acquisition of Propel Media
Next UO's $425M Ballmer Institute director on hiring staff, recruiting students